Crossreactive neutralizing antibodies induced by immunization with caprine arthritis-encephalitis virus surface glycoprotein

Vaccine

Volumn 18, Issue 13, 2000, Pages 1282-1287

  Kemp, R K ^a   Knowles, D P ^a,b   Perry, L L ^a   McGuire, T C ^a   Besser, T E ^a   Cheevers, W P ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

^b AGRICULTURAL RESEARCH SERVICE   (United States)

Author keywords

Caprine arthritis encephalitis lentivirus surface glycoprotein; Neutralizing antibody responses

Indexed keywords

MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; VIRUS GLYCOPROTEIN;

ANIMAL MODEL; ARTICLE; CAPRINE ARTHRITIS ENCEPHALITIS VIRUS; CROSS REACTION; GOAT; IMMUNIZATION; NONHUMAN; PRIORITY JOURNAL; SEROCONVERSION; SYNOVIUM; VIRUS INFECTION; VIRUS NEUTRALIZATION; VIRUS REPLICATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; ANTIBODY SPECIFICITY; ARTHRITIS-ENCEPHALITIS VIRUS, CAPRINE; CROSS REACTIONS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; GOATS; IMMUNOBLOTTING; IMMUNOGLOBULIN G; MEMBRANE GLYCOPROTEINS; NERVE TISSUE PROTEINS; NEUTRALIZATION TESTS; VIRAL VACCINES;

EID: 0033988710     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(99)00181-4     Document Type: Article

References (37)

1. Cease K.B., Berzofsky J.A. Toward a vaccine for AIDS: the emergence of immunobiology-based vaccine development. Annu Rev Immunol. 12:1994;923-989.
2. Pantaleo G., Fauci A.S. New concepts in the immunopathogenesis of HIV infection. Annu Rev Immunol. 13:1995;487-512.
3. Paul W.E. Can the immune response control HIV infection? Cell. 82:1995;177-182.
4. Haynes B.F., Pantaleo G., Fauci A.S. Toward an understanding of the correlates of protective immunity to HIV infection. Science. 271:1996;324-328.
5. Burns D.P.W., Desrosiers R.C. Envelope sequence variation, neutralizing antibodies, and primate lentivirus persistence. Curr Top Microbiol Immunol. 188:1994;185-219.
6. Fenyo E.M., Albert J., McKeating J. The role of the humoral immune response in HIV infection. AIDS. 10(Suppl A):1996;S97-S106.
7. Poignard P., Klasse P.J., Sattentau Q.J. Antibody neutralization of HIV-1. Immunol Today. 17:1996;239-246.
8. Parren P., Gauduin M.C., Koup R.A., Poignard P., Sattentau Q.J., Fisicaro P., Burton D.R. Relevance of the antibody response against human immnodeficiency virus type 1 envelope to vaccine design. Immunol Lett. 58:1997;125-132.
9. Moore J.P., Cao Y., Leu J., Qin L., Korber B., Ho D.D. Inter- and intra-clade neutralization of human immunodeficiency virus type 1: genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes. J. Virol. 70:1996;427-444.
10. Parren P., Mondor I., Naniche D., Ditzel H.J., Klasse P.J., Burton D.R., Sattentau Q.J. Neutralization of human immunodeficiency virus type 1 by antibody to gp120 is determined primarily by occupancy of sites on the virion irrespective of epitope specificity. J Virol. 72:1998;3512-3519.
11. Mascola J.R., Mathieson B.J., Zack P.M., Walker M.C., Halstead S.B., Burke D.S. Summary report: workshop on the potential risks of antibody-dependent enhancement in human HIV vaccine trials. AIDS Res Hum Retroviruses. 9:1993;1175-1184.
12. Sullivan N., Sun Y., Li J., Hofmann W., Sodroski J. Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line passaged human immunodeficiency virus type 1 isolates. J Virol. 69:1995;4413-4422.
13. Kostrikis L.G., Cao Y., Ngai H., Moore J.P., Ho D.D. Quantitative analyses of serum neutralization of human immunodeficiency virus type 1 from subtypes A, B, C, D, E, F and I: Lack of direct correlation between neutralization serotypes and genetic subtypes and evidence for prevalent serum-dependent infectivity enhancement. J Virol. 70:1996;445-458.
14. Cheevers W.P., Beyer J.C., Knowles D.P. Type 1 and type 2 cytokine gene expression by viral gp135 surface protein-activated T-lymphocytes in caprine arthritis-encephalitis lentivirus infection. J Virol. 71:1997;6259-6263.
15. Golding H., D'Souza M.P., Bradac J., Mathieson B., Fast P. Neutralization of HIV-1. AIDS Res Hum Retroviruses. 10:1994;633-643.
16. Lichtensteiger C.A., Knowles D.P., McGuire T.C., Cheevers W.P. Recombinant gp135 envelope glycoproteins of caprine arthritis-encephalitis lentivirus variants inhibit homologous and heterologous variant specific neutralizing antibodies. Virology. 185:1991;2-9.
17. Crawford T.B., Adams D.S., Cheevers W.P., Cork L.C. Chronic arthritis in goats caused by a retrovirus. Science. 207:1980;997-999.
18. Cork L.C., Hadlow W.J., Gorham J.R., Piper R.C., Crawford T.B. Infectious leukoencephalomyelitis of goats. J Infect Dis. 129:1974;134-141.
19. Narayan O., Clements J.E., Strandberg J.D., Cork L.C., Griffin D.E. Biological characterization of the virus causing leukoencephalitis and arthritis in goats. J Gen Virol. 50:1980;69-79.
20. Saltarelli M., Querat G., Konings D., Vigne R., Clements J.E. Nucleotide sequence and transcriptional analysis of molecular clones of CAEV which generate infection virus. Virology. 179:1990;347-364.
21. Knowles D.P., Cheevers W.P., McGuire T.C., Brassfield A.L., Harwood W.G., Stem T.A. Structure and genetic variability of envelope glycoproteins of two antigenic variants of caprine arthritis-encephalitis lentivirus. J Virol. 65:1991;5744-5750.
22. Wain-Hobson S., Sonigo P., Guyader M., Gazit A., Henry M. Erratic G→A hypermutation within a complete caprine arthritis-encephalitis virus (CAEV) provirus. Virology. 209:1995;297-303.
23. Valas S., Benoit C., Guionaud C., Perrin G., Mamoun R.Z. North American and French caprine arthritis-encephalitis viruses emerge from ovine maedi-visna viruses. Virology. 237:1997;307-318.
24. McGuire T.C., Norton L.K., O'Rourke K.I., Cheevers W.P. Antigenic variation of neutralization-sensitive epitopes of caprine arthritis-encephalitis lentivirus during persistent arthritis. J Virol. 62:1988;3488-3492.
25. McGuire T.C., Knowles D.P., Davis W.C., Brassfield A.L., Stem T.A., Cheevers W.P. Transmembrane protein oligomers of caprine arthritis-encephalitis lentivirus are immunodominant in goats with progressive arthritis. J Virol. 66:1992;3247-3250.
26. Cheevers W.P., Knowles D.P., Norton L.K. Neutralization-resistant antigenic variants of caprine arthritis-encephalitis lentivirus associated with progressive arthritis. J Infect Dis. 164:1991;679-685.
27. Browning M., Reid G., Osborne R., Oswald J. Incorporation of soluble antigens in ISCOMS: HIV gp120 ISCOMS induce virus neutralizaing antibodies. Vaccine. 10:1992;585-590.
28. Perry L.L., Wilkerson M.J., Hullinger G.A., Cheevers W.P. Depressed CD4+ T lymphocyte proliferative response and enhanced antibody response to viral antigen in chronic lentivirus-induced arthritis. J Infect Dis. 171:1995;328-334.
29. Cheevers W.P., McGuire T.C., Norton L.K., Cordery-Cotter R., Knowles D.P. Failure of neutralizing antibody to regulate CAE lentivirus expression in vivo. Virology. 196:1993;835-839.
30. Cheevers W.P., Knowles D.P., McGuire T.C., Baszler T.V., Hullinger G.A. Caprine arthritis-encephalitis lentivirus (CAEV) challenge of goats immunized with recombinant vaccinia virus expressing CAEV surface and transmembrane envelope glycoproteins. Vet Immunol Immunopathol. 42:1994;237-251.
31. Cheevers W.P., Knowles D.P., McGuire T.C., Cunningham D.R., Adams D.S., Gorham J.R. Chronic disease in goats orally infected with two isolates of caprine arthritis-encephalitis lentivirus. Lab Invest. 58:1988;510-517.
32. Sattentau Q.J., Moore J.P. Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oliomer. J Exp Med. 182:1995;185-196.
33. Mascola J.R., Snyder S.W., Weislow O.S., Belay S.M., Belshe R.B., Schwartz D.H., Clements M.L., Dolin R., Graham B.S., Gorse G.J., Keefer M.C., McElrath M.J., Walker M.C., Wagner K.F., McNeil J.G., McCutchan F.E., Burke D.S. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. J Infect Dis. 173:1996;340-348.
34. Fouts T.R., Binley J.M., Trkola A., Robinson J.E., Moore J.P. Neutralization of the human immunodeficiency virus type 1 primary isolate JR-FL by human monoclonal antibodies correlates with antibody binding the oligomeric form of the envelope glycoprotein complex. J Virol. 71:1997;2779-2785.
35. VanCott T.C., Mascola J.R., Kaminski R.W., Kalyanaraman V., Hallberg P.L., Burnett P.R., Ulrich J.T., Richtman D.J., Birx D.L. Antibodies with specificity to native gp120 and neutralization activity against primary human immunodeficiency virus type 1 isolates elicited by immunization with oligomeric gp160. J Virol. 71:1997;4319-4330.
36. Haigwood N.L., Nara P.L., Brooks E., van Nest G.A., Ott G., Higgins K.W., Dunlop N., Scandella C.J., Eichberg J.W., Steimer K.S. Native but not denatured recombinant human immunodeficiency virus type 1 gp120 generates broad-spectrum neutralizing antibodies in baboons. J Virol. 66:1992;172-182.
37. Kliks S.C., Shioda T., Haigwood N.L., Levy J.A. V3 variability can influence the ability of an antibody to neutralize or enhance infection by diverse strains of human immunodeficiency virus type 1. Proc Natl Acad Sci USA. 90:1993;11518-11522.